This requires Flash to play. Click here to download.

The information on this site is intended for health care professionals
in the United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL I AM NOT A HEALTHCARE PROFESSIONAL
Zolinza® [vorinostat] capsules Reactivate Expression
Home About ZOLINZA Efficacy Safety profile Dosage Reimbursement Resource center CTCL overview Prescribing Information Patient Information
Patient Product Information

ePrints

Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
J Clin Oncol. 2007;25:3109–3115.
Download reprint

Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109(1):31–39.
Download reprint

Duvic M, Olsen EA, Breneman D, et al. Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma (CTCL).
Clinical Lymphoma & Myeloma. 2009;9:412–416.
Download reprint


Home | Patient Information | Prescribing Information
ZOLINZA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

This site is intended only for health care professionals of the United States, its territories, and Puerto Rico.

20951007(12)-12/09-ZOL
For general information and other services for physicians
MERCK MEDICUSMERCK SOURCEMERCKServices
MerckMedicus, MerckSource, and MerckServices are trademarks of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.